Austrian diagnostics company on expansion course in the United Kingdom

The Viennese Medtech company MADX continues its expansion course and now takes over the sales of its allergy diagnostics products in the United Kingdom. The company is further expanding its position in one of the most growing health markets in Europe.

Alex, the most comprehensive molecular allergy blood test, has so far been marketed by a sales partner by the manufacturer Madx. Since the end of May 2025, Madx has been coordinating all sales and service activities himself and maintains a local team in the UK.

The step marks a strategic course. “”The United Kingdom is a key market for us with great growth potential – especially because many patients have so far have no access to comprehensive, precise allergy diagnostics“, erklärt CEO Dr. Christian harwanegg. „With direct market access, we want to help improve diagnostic care and thus noticeably increase the quality of life of people in the long term. At the same time, we can look after our customers: more intensely and use our scientific competence in the field of allergy diagnostics.“

MADX products are already in use in several renowned British facilities, including the Cambridge Clinical Laboratories, university clinics in Wales and Sussex as well as the London clinic. In the future, the company not only wants to deliver diagnostics products, but also want to set new standards in customer service with direct support and advice on site.

The takeover of the UK market is part of a broader expansion strategy: Sales are now being carried out directly through MADX in other European regions-including the Benelux countries and Scandinavia.

The market for molecular diagnostics is growing rapidly: According to forecasts, the global market volume is to increase to over $ 47 billion by 2032. Madx sees himself correctly positioned with his extensive diagnostic approach. The aim is to be able to give specialist staff in the health sector the most complete picture of the allergy situation of their patients – as the basis for a precise recommendation for therapy.